Levodopa/Benserazide Pch

Levodopa, the active ingredient in Levodopa/Benserazide Pch, is a Antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease and related Parkinsonian syndromes in adult patients.

GNH USA supplies Levodopa/Benserazide Pch as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Benserazide is indicated for disorders of the dopaminergic system, primarily Parkinsonian conditions.

Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. Parkinsonian syndrome: alleviates tremor, stiffness and gait disturbances. Secondary parkinsonism: helps control symptoms when caused by drug‑induced or vascular factors.

Levodopa/Benserazide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia - Dry mouth

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Neuroleptic malignant syndrome - Cardiac arrhythmias - Severe depression or suicidal thoughts

Levodopa/Benserazide requires careful clinical monitoring to minimise risks.

Dose titration: adjust gradually under medical supervision. Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. Psychiatric assessment: monitor for hallucinations, confusion or mood changes. Renal/hepatic impairment: use with caution and consider dose adjustment. Drug interactions: review concomitant medications for potential interactions. Pregnancy: safety not established; avoid unless benefits outweigh risks. Store at room temperature: keep in original container, protect from moisture and light.

Levodopa/Benserazide can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish therapeutic effect. - Irreversible MAO‑B inhibitors (e.g., selegiline): increase levodopa levels, risk of toxicity. - Antihypertensive agents (e.g., alpha‑blockers): may cause severe hypotension. - Serotonergic drugs (e.g., SSRIs, triptans): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - Diuretics: may enhance orthostatic hypotension; monitor blood pressure.